Physician's Weekly
JUNE 19, 2025
High blood urea nitrogen to albumin ratio values in patients with CKD are linked to greater mortality, indicating its potential value as a prognostic indicator. Adjusted Cox regression analysis confirmed the increased 28-day mortality risk in patients with a higher BAR. By tertile, mortality rates were 14.6% in Tertile 1 (BAR, ≤9.8
Common Sense Family Doctor
JANUARY 19, 2025
Most patients who choose colonoscopy as a screening test for colorectal cancer are referred from primary care to a gastroenterologist or other specialist who performs endoscopy. But that wasn’t the case for the estimated 1 in 15 US patients whose screening colonoscopies were performed by family physicians in 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Permanente Medicine
MAY 22, 2025
As an experienced physician leader, she is known for always going the extra mile for our patients and colleagues. ” Dr. She has held a variety of leadership positions within the organization dedicated to maintaining and advancing high-quality care that delivers value and superior outcomes for patients.
The Clinical Problem Solvers
APRIL 24, 2025
Her mission — preparing the next generation of diverse physician leaders in pediatric healthcare and mental health and creating partnerships between communities and academic centers — will be critical for eliminating disparities among minority populations. A Culturally Informed Approach to Supporting Suicidal Minoritized Patients.
GeriPal
JANUARY 12, 2023
Which patients are eligible to go to an ACE unit? So I picked the Ed Sheeran song, The A Team, because it reminds me of our ACE team that goes around the hospital and cares for our older patients. And a light bulb just went off in my head, like, yes, this makes sense as a model for how we should care for more complex older patients.
FDA Law Blog
MAY 3, 2021
for failure to submit the required information following completion of a clinical trial evaluating the safety and effectiveness of the drug dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (see FDA press release announcing the Notice of Noncompliance here ). 42 C.F.R. §§ 11.10, 11.44(a).
FDA Law Blog
MAY 3, 2021
for failure to submit the required information following completion of a clinical trial evaluating the safety and effectiveness of the drug dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (see FDA press release announcing the Notice of Noncompliance here ). 42 C.F.R. §§ 11.10, 11.44(a).
Expert insights. Personalized for you.
52 
Let's personalize your content